1.Assessment of Prognostic Factors of Racial Disparities in Testicular Germ Cell Tumor Survival in the United States (1992-2015).
Jing WU ; Yi Bing JI ; Bi Wei TANG ; Matthew BROWN ; Bao Hua WANG ; Chen Lei DU ; Jian Shu DU ; Xue Mei WANG ; Li Jun CAI ; Guo Yi WU ; Yan ZHOU
Biomedical and Environmental Sciences 2021;34(2):152-162
Objective:
Testicular germ cell tumors (TGCT) are the most common cancer among men aged 15 to 39 years. Previous studies have considered factors related to TGCT survival rate and race/ethnicity, but histological type of the diagnosed cancer has not yet been thoroughly assessed.
Methods:
The data came from 42,854 eligible patients from 1992 to 2015 in the Surveillance Epidemiology and End Results 18. Frequencies and column percent by seminoma and nonseminoma subtypes were determined for each covariates. We used Cox proportional hazard regression to assess the impact of multiple factors on post-diagnostic mortality of TGCT.
Results:
Black males were diagnosed at a later stage, more commonly with local or distant metastases. The incidence of TGCT in black non-seminoma tumors increased most significantly. The difference in survival rates between different ethnic and histological subtypes, overall survival (OS) in patients with non-seminoma was significantly worse than in patients with seminoma. The most important quantitative predictor of death was the stage at the time of diagnosis, and older diagnostic age is also important factor affecting mortality.
Conclusion
Histological type of testicular germ cell tumor is an important factor in determining the prognosis of testicular cancer in males of different ethnic groups.
Adult
;
Health Status Disparities
;
Humans
;
Male
;
Neoplasms, Germ Cell and Embryonal/pathology*
;
Prognosis
;
Risk Factors
;
SEER Program/statistics & numerical data*
;
Seminoma/pathology*
;
Survival Rate/trends*
;
Testicular Neoplasms/pathology*
;
United States/ethnology*
2.The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone.
Haider MAHDI ; Benjamin NUTTER ; Fadi ABDUL-KARIM ; Sudha AMARNATH ; Peter G ROSE
Journal of Gynecologic Oncology 2016;27(2):e19-
OBJECTIVE: To investigate the impact of pelvic radiation on survival in patients with uterine serous carcinoma (USC) who received adjuvant chemotherapy. METHODS: Patients with stage I-IV USC were identified from the Surveillance, Epidemiology, and End Results program 2000 to 2009. Patients were included if treated with surgery and chemotherapy. Patients were divided into two groups: those who received chemotherapy and pelvic radiation therapy (CT_RT) and those who received chemotherapy only (CT). Kaplan-Meier curves and Cox regression proportional hazard models were used. RESULTS: Of the 1,838 included patients, 1,272 (69%) were CT and 566 (31%) were CT_RT. Adjuvant radiation was associated with significant improvement in overall survival (OS; p<0.001) and disease-specific survival (DSS; p<0.001) for entire cohort. These findings were consistent for the impact of radiation on OS (p<0.001) and DSS (p<0.001) in advanced stage (III-IV) disease but not for early stage (I-II) disease (p=0.21 for OS and p=0.82 for DSS). In multivariable analysis adjusting for age, stage, race and extent of lymphadenectomy, adjuvant radiation was a significant predictor of OS and DSS for entire cohort (p=0.003 and p=0.05) and in subset of patients with stage III (p=0.02 and p=0.07) but not for patients with stage I (p=0.59 and p=0.49), II (p=0.83 and p=0.82), and IV USC (p=0.50 and p=0.96). Other predictors were stage, positive cytology, African American race and extent of lymphadenectomy. CONCLUSION: In USC patients who received adjuvant chemotherapy, adjuvant radiation was associated with significantly improved outcome in stage III disease but not for other stages. Positive cytology, extent of lymphadenectomy and African race were significant predictors of outcome.
Adult
;
African Americans/statistics & numerical data
;
Aged
;
Aged, 80 and over
;
Carcinoma, Papillary/pathology/radiotherapy/*therapy
;
Chemoradiotherapy, Adjuvant
;
Chemotherapy, Adjuvant
;
Female
;
Humans
;
Hysterectomy
;
*Lymph Node Excision
;
Middle Aged
;
Neoplasm Staging
;
SEER Program
;
Survival Rate
;
Uterine Neoplasms/pathology/radiotherapy/*therapy
3.Trends in outpatient breast cancer surgery among Medicare fee-for-service patients in the United States from 1993 to 2002.
Chinese Journal of Cancer 2011;30(3):197-203
The practice of outpatient breast cancer surgery has been controversial in the United States. This study aimed to update time trends and geographic variation in outpatient breast cancer surgery among elderly Medicare fee-for-service women in the United States. Using the 1993-2002 linked Surveillance, Epidemiology and End Results (SEER)-Medicare claims data and the Area Resource Files, we identified 2 study samples, including the women whose breast cancers were the first-ever-diagnosed cancer at age 65 years or older from 9 regions continuously covered by the SEER registries since 1993. The first sample included the women receiving unilateral mastectomy for stage 0-IV cancer; the second included the women receiving the breast-conserving surgery with lymph node dissection (BCS/LND) for stage 0-II cancer. The proportions of patients receiving outpatient surgery increased from 3.2% to 19.4% for mastectomy and from 48.9% to 77.8% for BCS/LND from 1993 to 2002. We observed substantial geographic variation in the average proportion of the patients receiving outpatient surgery in the studied areas across the 10-year period, ranging from 3.9% in Connecticut to 27.2% in Utah for mastectomy and from 54.7% in Hawaii to 78.1% in Seattle, Washington, for BCS/LND. As the popularity of outpatient breast cancer surgery continues to grow, more evidence-based analyses related to quality and outcomes of outpatient breast cancer surgery among various populations are needed in order to facilitate the public debates about state and federal mandated health benefit legislations.
Aged
;
Ambulatory Surgical Procedures
;
statistics & numerical data
;
trends
;
Breast Neoplasms
;
pathology
;
surgery
;
Connecticut
;
Fee-for-Service Plans
;
statistics & numerical data
;
Female
;
Hawaii
;
Humans
;
Lymph Node Excision
;
statistics & numerical data
;
Mastectomy
;
statistics & numerical data
;
Mastectomy, Segmental
;
statistics & numerical data
;
Medicare
;
Neoplasm Staging
;
SEER Program
;
United States
;
Utah
;
Washington

Result Analysis
Print
Save
E-mail